Last €91.91 EUR
Change Today -4.05 / -4.22%
Volume 455.0
LO3 On Other Exchanges
SIX Swiss Ex
As of 7:09 AM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LO3) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/22/14 - €98.24
52 Week Low
10/31/13 - €62.59
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LONZA GROUP AG-REG (LO3)

Related News

No related news articles were found.

lonza group ag-reg (LO3) Related Businessweek News

View More BusinessWeek News

lonza group ag-reg (LO3) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. It operates in two segments, Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, antibody drug conjugates, and cytotoxic and peptide syntheses, as well as biological cellular and gene therapies. This segment also offers cell culture, transfection, and molecular biology tools for lifescience research; media used in the production of therapeutics; endotoxin detection assays; products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas; and cell biology solutions to enhance efficiencies in research. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. The Specialty Ingredients segment offers personal care and preservation products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B3 compounds and L-Carnitine, as well as nutritional ingredients used in pharmaceuticals, human energy drinks, and animal feeds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields; sanitizers and other treatment chemicals, as well as feeder systems for drinking water disinfection and surface-water treatments; industrial Solutions, such as preservatives and biocide blends; and products and services that enhance the quality of wood. The company was founded in 1897 and is headquartered in Basel, Switzerland.

9,761 Employees
Last Reported Date: 07/24/14
Founded in 1897

lonza group ag-reg (LO3) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lonza group ag-reg (LO3) Key Developments

Lonza Group Ltd. Launches Vaccine Design and Development Services Platform

Lonza Group Ltd. launched Vaccine Design and Development Services platform. This platform includes in silico and in vitro tools to accelerate the design and assessment of vaccine candidates for their ability to provoke an effective immune response. Allowing companies to focus on the most promising vaccine candidates early in the process can help reduce time and costs, maximizing R&D resources. Lonza is uniquely positioned to offer customers these services that include Epibase In Silico (IS) and In Vitro (IV) tools for immunogenicity assessment. Epibase is a predictive tool driven by structural bioinformatics in conjunction with experimental data. This tool can predict potential peptide/HLA binding, which can be used to rationally design an efficacious vaccine. Enhancements enable extensive prediction of both HLA Class I CD8+ and Class II CD4+ T cell epitopes, strengthening the ability of Epibase IS to support lead vaccine candidate selection and optimization. The Epibase IV screening services include a wide range of assays designed to assess immune responses raised by vaccine candidates. High-quality peripheral blood mononuclear cells (PBMCs) from human donors are used allowing for the comparison and ranking of candidates in healthy and/or specific diseased populations. A wide variety of antigens, including whole proteins, protein complexes, peptides, viruses, Virus Like Particles (VLPs), virosomes, and adjuvants can be tested with the Epibase IV tools. As in vitro testing requires milligram quantities of vaccine candidates, Lonza offers the Light Path Custom Material Supply Service for small-scale production of proteins. The Light Path Discovery Service is a streamlined process that can provide sufficient product for in vitro assessment of vaccine immunogenicity. The Light Path service includes access to mammalian and microbial expression systems, which can to a seamless transition into larger-scale cGMP manufacturing for later development stages.

Lonza Launches New Emollient Ester for Skin Care

Lonza Group Ltd. has launched a new Lonzest DC Emollient Ester that reportedly offers spreadability on the skin and skin-conditioning properties for personal care formulators. Representing the latest multi-functional ingredient from Lonza, Lonzest DC (dicaprylyl carbonate) is a light ester emollient that conditions skin with superior solubility of UV sun filters. It has excellent pigment-wetting properties and is a silicone-free alternative. The product helps give a light, dry, powdery feel to the skin so that the skin doesn't feel oily or greasy despite the application of a sunscreen or face lotion. Lonzest DC can be used in sunscreens, color cosmetics, daily facial lotions, overnight serums and non-greasy aesthetic formulations.

Lonza Group Ltd Reports Unaudited Earnings Results for the Six Months Ended June 30, 2014; Reiterates Earnings Guidance for the Year of 2014

Lonza Group Ltd. reported unaudited earnings results for the six months ended June 30, 2014. For the period, the company reported sales of CHF 1,800 million compared to CHF 1,744 million a year ago. EBIT was CHF 215 million compared to CHF 112 million a year ago. Profit before income taxes was CHF 174 million compared to CHF 49 million a year ago. Profit for the period, attributable to the equity holder of the parent was CHF 140 million or CHF 2.68 per diluted share compared to CHF 41 million or CHF 0.79 per diluted share a year ago. Net cash provided by operating activities was CHF 163 million compared to CHF 101 million a year ago. Purchase of property, plant & equipment and intangible assets was CHF 70 million compared to CHF 86 million a year ago. Net purchase of other assets was CHF 4 million compared to CHF 9 million a year ago. EBITDA was CHF 362 million compared to CHF 334 million a year ago. Operational free cash flow was CHF 124 million compared to CHF 68 million a year ago. Net debt as at June 30, 2014 was CHF 2,113 million compared to CHF 2,417 million a year ago. Core EBITDA was CHF 368 million compared to CHF 346 million a year ago. Core result from operating activities was CHF 241 million compared to CHF 213 million a year ago. Core profit for the period was CHF 162 million or CHF 3.10 per diluted share compared to CHF 127 million or CHF 27 per diluted share a year ago. Core RONOA was 14.5% compared to 11.8% a year ago. RONOA was 10.5% compared to 6.6% a year ago. The company reiterated its full-year 2014 outlook with a core EBIT growth of 10% and sales growth of 5%. The capital expenditure in 2014 will remain well below CHF 300 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LO3:GR €91.91 EUR -4.05

LO3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $57.35 USD +0.16
Clariant AG SFr.16.80 CHF +0.20
Croda International PLC 2,302 GBp +42.00
Symrise AG €44.90 EUR +0.59
Wacker Chemie AG €95.12 EUR +2.71
View Industry Companies

Industry Analysis


Industry Average

Valuation LO3 Industry Range
Price/Earnings 29.5x
Price/Sales 1.5x
Price/Book 2.6x
Price/Cash Flow 29.9x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at